Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,764.38 -182.55 (-0.47%) Hang Seng
19,220.62 -415.60 (-2.12%) FTSE 100
8,416.45 -7.75 (-0.09%) Bitcoin USD
70,117.36 -1,178.20 (-1.65%) CMC Crypto 200
1,526.78 +38.24 (+2.57%)
Sutro Biopharma, Inc. (STRO)
After hours:
- GlobeNewswire
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in combination with bevacizumab; enrollment is expected to complete in the first half of 2024 - - The randomized portion of REFRαME-O1, the registration-enabling study of luvelta for patients with platinum-resistant ovarian cancer, is
- Zacks
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
Sutro Biopharma (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
The past three years for Sutro Biopharma (NASDAQ:STRO) investors has not been profitable
Every investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So...
